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MrgD,amemberoftheMas-relatedgenefamily,isexpressedexclusivelyinsmalldiameterIB4
+ neuronsinthedorsalrootganglion.
This unique expression pattern, the presence of a single copy of MrgD in rodents and humans, and the identiﬁcation of a putative
ligand,beta-alanine, make itanexperimentally attractive therapeutic targetforpainwithlimitedlikelihood ofsideeﬀects.Wehave
devised a high throughput calcium mobilization assay that enables identiﬁcation of both agonists and antagonists from a single
screenforMrgD.ScreeningoftheLibraryofPharmacologicallyActiveCompounds(LOPAC)validatedthisassayapproach,andwe
identiﬁed both agonists and antagonists active at micromolar concentrations in MrgD expressing but not in parental CHO-DUKX
cell line. Further characterization was performed using a subset of these screening hits. Our results demonstrated that the dual
agonist/antagonist assay format is feasible and likely can be extended to most GPCRs with known agonist.
1.Introduction
The seven transmembrane G-protein coupled receptors
(GPCRs) comprise one of the largest gene families in the
human genome and represent an estimated 25% of all drug
targets [1]. They are activated by a variety of molecules
including, but not limited to, neurotransmitters, peptides,
lipids, odorants, and light, and thus participate in a wide
range of physiological responses. Reverse pharmacology
strategies are usually employed in the identiﬁcation of
ligands for newly identiﬁed GPCRs. These ligands are in
turn used for the pharmacological characterization and
identiﬁcation of the physiological role of these receptors [2].
Recent studies have identiﬁed a GPCR subfamily pre-
dominantly expressed in small diameter IB4+ neurons in the
dorsal root ganglion (DRG) and as such, might have a role
in nociception. Members of this family have been referred to
as Mas-related genes (Mrgs) [3] or sensory neuron speciﬁc
receptors (SNSRs) [4] .I nm i c e ,t h eM r gf a m i l yi sc o m p r i s e d
of three large subfamilies (MrgA, MrgB, and MrgC) and
six single copy genes (MrgD, MrgE, MrgF/RTA, MrgG,
MrgH/GPR90, and MAS1), that together comprise ∼50
distinct sequences [3]. The functional signiﬁcance of this
cellular heterogeneity among murine nociceptive sensory
neurons is currently not known. In contrast, there are only
fourfunctionalMrgX/SNSRgenesinhumans;however,none
of the human MrgX and mouse MrgA, B, or C genes are
strictly orthologous, making investigation of their function
or testing of compounds in relevant rodent models diﬃcult.
Importantly, the single copy genes MrgD, MrgE, MrgF, and
MrgG have clearly deﬁned human, mouse, and rat orthologs
and thus may represent experimentally tractable targets for
the development of pain therapies [3, 5].
Though many Mrg family members are classiﬁed as
orphan receptors, ligands for a number of these receptors
have been identiﬁed, and are being used as tools to
characterize their role in nociception. These receptor/ligand
pairs include human MrgX2/cortistatin [6], human
MrgX1 (SNSR4), SNSR3, and rat MrgC/BAM22 (bovine
adrenal medulla peptide) [4, 7], and MrgA1, MrgA4, and2 Journal of Biomedicine and Biotechnology
MrgC11/RF-amide neuropeptides [3, 8]. Beta-alanine was
identiﬁed as a ligand for MrgD, speciﬁcally evoking an
intracellular Ca2+ response in CHO cells expressing human,
rat, or mouse MrgD [9]. Grazzini et al. studied nociception
resulting from the activation of rat MrgC by its ligand
BAM22 [7]. Selective MrgC agonists produced spontaneous
pain behavior suggesting that an antagonist of this receptor
may be of therapeutic value in treating pain. A cell-based
beta-lactamase (BLA) reporter gene assay to identify small
molecule antagonists of the human MRGX1 receptor also
has been reported [10]. Though beta-alanine has been
identiﬁed as a putative agonist for MrgD [9], studies have
not been reported describing its eﬀects on pain.
By virtue of its cross-species conservation as a single-
copy gene as well as its restricted expression to small
diameter nociceptive neurons, MrgD represents an attractive
target for the development of pain therapeutic agents, an
endeavor that would be facilitated by the identiﬁcation
of potent agonists and antagonists. A FLIPR based screen
for MrgA and MrgD agonists [11] has been published
recently, but no method for identifying MrgD antagonist
has been yet reported. The objective of the current study
was to develop a MrgD assay amenable to high throughput
screening(HTS)thatiscapableofsimultaneouslyidentifying
agonists and antagonists. Screening compound libraries in
this assay format could be useful in the identiﬁcation of tool
compounds to probe the physiological role(s) of MrgD.
2.MaterialsandMethods
2.1. Chemicals and Reagents. Beta-alanine, GABA, glycine,
and the LOPAC640 library were obtained from Sigma (St.
Louis, MO). A MrgX1 (SNSR4) cell line was purchased from
Multispan(Hayward,CA).Allcellculturereagentswerefrom
Invitrogen (Carlsbad, CA).
2.2. MrgD Stable Cell Line Generation. Human MrgD
(Accession number AY427820) was ampliﬁed from human
genomic DNA (Clontech, Palo Alto, CA) by PCR using
the forward primer Xba15  -CTAG TCT AGA GCC GCC
ACC ATG TAC CCA TAC GAT GTT CCA GAT TAC GCT
AAC CAG ACT TTG AAT AGC AGT-3  and the reverse
primer EcoR15  -CCG GAA TTC TCA AGC CCC CAT
CTC ATT GGT-3 . A Kozak sequence and HA epitope
tag were incorporated in the forward primer. Rat MrgD
(Accession number AF518246) was ampliﬁed and cloned
similarly using the forward primer Xba15  -CTAG TCT
AGA GCC GCC ACC ATG GAA CAA AAA CTT ATT
TCT GAA GAA GAT CTG AAC TAC ACT CCT TAT AGC
AGC C-3  and the reverse primer EcoR15  -CCG GAA TTC
TCA GAC CCC ATC ATT AGT ACA TGT-3  using rat
genomic DNA (Clontech, Palo Alto, CA) as template. A
Kozak sequence and c-Myc epitope tag were incorporated
in the forward primer. The resulting PCR products were
cloned into the Xba Ia n dEcoR I sites of pHTOP vector,
a proprietary derivative of the pED expression vector [12].
For transfection, CHO-DUKX-A2 cells (DHFR(−)C H Oc e l l
line stably expressing the tetracycline transactivator) were
grown in M alpha media containing 1% MEM nonessential
amino acids solution (NEAA), 10% fetal bovine serum
(FBS), and 500ug/mL G418. MrgDpHTOP was transfected
using Lipofectamine Plus reagents as per the manufacturer’s
recommendations. Antibiotic selection was performed using
Dulbecco’s modiﬁed Eagle medium supplemented with 10%
FBS, 100units/mL penicillin, 100μg/mL streptomycin, 1%
NEAA, and 20nM methotrexate (Calbiochem, San Diego,
CA). Cell lines were maintained at 37◦C in a humidiﬁed
atmosphere containing 5% CO2. Surviving colonies were
expanded further and used for functional analysis. Clones of
humanMrgDexpressingcelllineswereevaluatedinitiallyfor
MrgD transcript level by Taqman analysis and normalized
against the house-keeping gene GAPDH (Glyceraldehyde-3-
phosphate dehydrogenase).
2.3. [Ca2+] FLIPR Assays. CHO-DUKX-A2 cells stably
expressing human or rat MrgD were plated in 384-well
tissue-culture-treated polystyrene black clear ﬂat-bottom
assay plates (BD Biosciences, San Jose, CA). Thirty μL
of 8 × 105 cells/mL (24,000 cells/well) were plated and
maintained for ∼24hrs at 37◦C in a humidiﬁed atmosphere
containing 5% CO2. After removal of the growth medium,
cells were incubated with 30μL of Ca3 dye (Molecular
Devices Corporation, Sunnyvale, CA) containing 2.5mM
freshly prepared probenecid made according to the man-
ufacturer’s protocol. Agonists were prepared in 1x Hanks
balanced salt solution (HBSS) buﬀer with 20mM HEPES
buﬀer. Changes in intracellular Ca2+ were monitored using
the Fluorometric Imaging Plate Reader (FLIPR; Molecular
Devices, Sunnyvale, CA). For the double addition protocols,
compounds were added by the FLIPR, and readings were
taken for 3min, followed by the addition of the agonist.
The change in intracellular calcium [Ca2+] was monitored
as an increase in relative ﬂuorescence units (RFUS), and
the diﬀerence between maximum and minimum RFU was
used to calculate dose-response curves. Data analysis was
performed using PRISM 4.0 (GraphPAD Software Inc.). For
theLOPACscreen,cellswereplatedin96-welltissue-culture-
treated polystyrene black clear ﬂat-bottom assay plates (BD
Biosciences, San Jose, CA). One hundred μL of cells (40,000
cells/well) were plated and maintained under the same
conditions as above. For the assay, growth medium was
replaced with 90μL of Ca3 dye containing 2.5mM freshly
preparedprobenecid.TheFLIPRadded10μLofbeta-alanine
at 100μM ﬁnal concentration. For antagonist dose-response
assays, the cells were incubated with the compounds for ∼30
minutes after which beta-alanine at a ﬁnal concentration of
10μMw a sa d d e db yt h eF L I P R .
3. Results
3.1. Characterization of Human and Rat MrgD Cell Lines.
Clones of human MrgD expressing cell lines were expanded
and evaluated initially for MrgD transcript level by Taqman
analysis. MrgD transcripts were detected in 25 clones
displaying wide-ranging expression levels (data not shown).
Eleven clones spanning this expression range were selectedJournal of Biomedicine and Biotechnology 3
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Figure 1: Concentration response for beta-alanine, GABA, and
glycine on rat MrgD receptor in CHO-DUKX cells. Representative
datafromcalciummobilizationFLIPRassayperformedin384wells
are shown. Each data point represents mean of 32 replicates, and
error bar represents SD. Human MrgD expressing CHO-DUKX
cells also had similar dose response (data not shown).
for FLIPR studies. The parental cell line was also evaluated,
and MrgD transcript was absent in CHO-DUKX cells.
Surprisingly, two clones, one with medium and the other
with low transcript levels, responded best to beta-alanine,
while three clones with high MrgD transcript levels showed
no response. Thus, our studies indicate that MrgD RNA
expression inversely correlated with larger beta-alanine-
induced calcium transient functional responses as assessed
by FLIPR responses (data not shown). Hence, when cell lines
expressing rat MrgD were generated, they were screened for
responses to beta-alanine only by FLIPR. The beta-alanine
EC50 values obtained for both human and rat MrgD cell
lines were in the1–4μM range. Further characterizations
of MrgD receptor-expressing cell lines were performed by
evaluating responses to ligands structurally similar to beta-
alanine, such as GABA and glycine. Figure 1 shows agonist
dose-response curves indicating that beta-alanine is the most
potent ligand followed by GABA and glycine, respectively.
The EC50 values of beta-alanine obtained for human and rat
MrgD are displayed in Table 1. In light of their structural
similarity to GABA, both gabapentin and pregabalin were
evaluated by FLIPR, but these drugs failed to induce a
response in either the human or rat MrgD expressing cells.
3.2. Evaluation of Gi and Gq Coupling of MrgD Receptors
UsingFLIPR. MrgDisknowntocouplethroughbothGiand
Gq [9]. To further explore the utility of the cell line for a
potential secondary assay measuring cAMP, we investigated
whether the FLIPR assay was capable of distinguishing the
extent of Gi and Gq coupling of MrgD. MrgD CHO-DUKX
cells were treated with either the Gi inhibitor pertussis toxin
Table 1: EC50 values obtained for MrgD agonists. Data represents
mean ± standard deviation from 2–6 independent experiments.
Ligand EC50 in μM
Human MrgD Rat MrgD
Beta-alanine 3.76 ±1.27 3.77 ± 0.87
GABA 53 ±26 49.8 ±1.5
Glycine >100 >100
Gabapentin No eﬀect No eﬀect
Pregabalin No eﬀect No eﬀect
(PTX) overnight or the phospholipase C (PLC) inhibitor
U-73122 for 30 or 60 minutes and then evaluated for
their responses to beta-alanine. U-73122 completely blocked
the FLIPR response (Figure 2(a)) but treatment with PTX
resulted in approximate 50% reduction in calcium mobiliza-
tion (Figure 2(b)), suggesting that the residual beta-alanine-
inducedresponseinCHO-DUKXcellsistransducedthrough
the coupling of MrgD to a PTX-insensitive G protein, most
likely Gq.
3.3. Assay Development and LOPAC Library Screen. We
developed an assay that could allow both agonists and
antagonists to be distinguished in a single screen. Employing
such an assay format should enable the identiﬁcation of tool
compounds that may help in elucidating the role of MrgD
in pain. The diagram in Figure 3 describes the dual-addition
assay format where addition of the test compound (addition
1) is followed by the addition of beta-alanine (addition 2).
A FLIPR response immediately upon the addition of a test
compound would indicate its activity as an agonist. On the
other hand, if the compound behaves as an antagonist, not
only will there be a lack of response to this test compound,
it will also attenuate the eﬀects of the subsequent addition of
beta-alanine. In the event of no receptor engagement by the
test compound, a normal agonist response will be observed
to beta-alanine. We validated this assay format, which was
robust and consistent with a Z  factor greater than 0.7.
To conﬁrm that the dual-addition FLIPR assay format
can be extended to a HTS platform, a screen of the
LOPAC library was performed (Figures 4(a) and 4(b) show
representative FLIPR traces). Initial evaluation of the results
from the dual assay format indicated that the assay was
sensitive enough to identify both agonists and antagonists.
The response to test compound GABA in the LOPAC
screening is shown in Figure 4(a) (row G, column 6). GABA
evoked a response, but as it is less potent than beta-alanine,
some calcium mobilization also was induced in response to
beta-alanine, albeit weaker when compared to other wells.
On the other hand, when the ﬁrst test compound was an
antagonist occupying the MrgD receptor, no initial eﬀect
was detected, and there was an attenuation or complete
absence of calcium mobilization following addition of beta-
alanine (C3, G4, G7, and E11-Chlorpromazine hydrochlo-
ride, R(−)-Propyl-norapomorphine hydrochloride, indatra-
line hydrochloride and, thioridazine hydrochloride, resp., in
Figure 4(b)). Screening the library in parallel on parental4 Journal of Biomedicine and Biotechnology
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Figure 2: Evaluation of Gq (Figure 2(a)) and Gi (Figure 2(b)) coupling of MrgD receptors assessed using FLIPR response. MrgD cells were
pretreated with the PLC inhibitor (U-73122 at 2μM for 30 or 60 minutes) or pertussis toxin (100ng overnight) for blocking Gi coupling to
MrgD. FLIPR responses were evaluated by the addition of 100μM beta-alanine.
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Figure 3: Assay format for the identiﬁcation of an agonist and
antagonist from a single screen. Test compound is added ﬁrst
followed by a second addition of beta-alanine. An agonist will
induce a FLIPR response immediately upon the addition of a test
compound. An antagonist will cause a pharmacological blockade
of the MrgD receptor resulting in attenuation or complete lack of
response to beta-alanine. In the event of no receptor engagement,
a normal agonist response will be observed from beta-alanine
addition.
CHO-DUKX cells helped in identifying compounds caus-
ing nonspeciﬁc calcium mobilization (example seen in
Figure 4(b), H5). Eliminating compounds that induced
calcium mobilization in the parental line ensured that
the agonists identiﬁed interact speciﬁcally with MrgD. To
evaluate whether this assay format could be extended to
other GPCR family members, we tested MrgX1 (SNSR4) cell
lines and performed a similar dual-addition format LOPAC
screen using its ligand BAM22 to identify antagonists.
Our results demonstrated that this assay format could be
Table 2: Compounds exhibiting agonism at the MrgD receptor and
not the parental CHO-DUKX cells.
Agonist
EC50 in μM
Human
MrgD
Rat
MrgD
5, 7 dihydroxytryptamine creatinine sulfate 5.2 9.7
Xanthine amine congener >100 48.3
(±) HA 966 11.0 13.2
applied to another GPCRs with a known agonist (data not
shown).
In addition to GABA, three other agonists that stim-
ulated MrgD expressed in the CHO-DUKX cell line but
not the parental cell line were obtained from the LOPAC
library screen (Table 2). One of these, (±) HA 966 is
a racemic mixture, and so the enantiomers were tested
separately. As displayed in Figure 5(a) the (−) HA 966
enantiomer was the most potent MrgD agonist (EC50
5.5μM) when compared to the racemic mixture (EC50
11μM) and (+) HA 966 enantiomer (EC50 106μM). In
addition to agonists, eight MrgD antagonist compounds
were also identiﬁed from the LOPAC screen. Though
compounds representing eight diﬀerent structural classes
were identiﬁed from the LOPAC library screen, only three
dopaminergic compounds chlorpromazine hydrochloride
(IC50 2.73E-06), thioridazine hydrochloride (IC50 1.06E-
06), and R(−)-Propylnorapomorphine hydrochloride (IC50
1.46E-06)couldbeconﬁrmedbydoseresponseanalysis.Two
representative compounds thioridazine and chlorpromazine
are shown in Figure 5(b). The percentage of hits conﬁrmed
after concentration response followup assay evaluation were
0.6% and 0.4% for agonists and antagonists, respectively
(Table 3).Journal of Biomedicine and Biotechnology 5
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Figure 4: Representative FLIPR traces obtained from LOPAC screen. Compounds from the LOPAC library were applied followed by the
addition of beta-alanine. Similar responses were observed for human and rat MrgD cell lines. Parental CHO-DUKX cell lines were also
tested to identify nonspeciﬁc eﬀects of test compounds. Green, red, and yellow traces represent agonist, antagonist, and nonspeciﬁc traces,
respectively.
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Figure 5: Illustration of the dose-response curve of selected agonists and antagonists. An agonist identiﬁed, (±) HA 966, is a racemic
mixture, and further characterization of the positive and negative enantiomers showed that the latter was the most potent MrgD agonist
among all three (Figure 4(a)). The EC50 values were 11, 106, and 5.5μM for the racemic mixture, positive, and negative isoforms of the
compound, respectively. Figure 4(b) shows two representative MrgD antagonists thioridazine and chlorpromazine, with IC50 values of 1.5
and 2.7μM, respectively.
4. Discussion
An inherent diﬃculty in the pursuit of novel therapeutic
targets is the lack of molecular and/or pharmacological
tools. Several approaches are usually employed, often in
parallel, to obtain insight into the functional role of
novel receptors in disease states. The scientiﬁc rationale
for pursuing drug discovery eﬀorts is often supported by
the degree to which a particular target is amenable to
available drug discovery technologies, its tissue localization,
changes in gene expression, availability of gain or loss of
function transgenic animals, and the availability of tool
compounds. Receptor-ligand interactions vary, and ligands
can function as agonists, antagonists, partial antagonists,6 Journal of Biomedicine and Biotechnology
Table 3: Structural class of compounds obtained from LOPAC
library screen that were conﬁrmed in dose-response FLIPR assay.
Structural class Percentage of
conﬁrmed hits
Agonists
Serotonergics, glutamatergics,
adenosine purinergic, and
Gabaergics
0.6
Antagonists Dopaminergic 0.4
or inverse agonists. Availability of any of these classes of
compounds as pharmacological tools can provide insight
into the physiological role of the receptor.
MrgD, a member of the Mas-related gene family [3, 5],
is speciﬁcally expressed in small diameter IB4+ neurons in
the dorsal root ganglion, an expression pattern that suggests
that MrgD play a role in the initiation or modulation of pain
signals and, as such, could be a novel target for the develop-
mentofpaintherapeuticagents.Elegantaxonaltracerstudies
have shown that MrgD is expressed in a subpopulation of
nonpeptidergic, nociceptive neurons that project exclusively
to the skin. These neurons innervate a speciﬁc layer of
the epidermis, distinct from that innervated by peptidergic
nerve ﬁbers [13]. To better understand the role of MrgD in
pain, our group has undertaken studies examining MrgD
modulation of ion channels thought to be involved in pain
signal transduction. We have observed a novel interaction
between MrgD and KCNQ/M-type potassium channels that
results in suppression of these channels and enhancement
of the excitability of DRG neurons [14]. These studies
suggest that antagonism of MrgD could be beneﬁcial for the
treatment of pain. Genetic ablation of mouse neurons that
express MrgD in adulthood caused speciﬁc deﬁcits in the
behavioral response to noxious mechanical stimuli but not
to noxious heat or cold stimuli [15].
Beta-alaninehasbeenidentiﬁedasaligandforMrgD[9].
Beta-alanine is a small amino acid structurally related to the
major inhibitory neurotransmitters gamma-aminobutyric
acid (GABA) and glycine. Our studies conﬁrmed the previ-
ous ﬁnding that GABA, but not glycine, weakly stimulated
cells expressing human and rat MrgD [9]. It has been
reportedthatbeta-alaninedecreasesglutamatergicexcitation
by binding to, and thus competing for, the glycine co-
agonist site of the N-methyl-D-aspartate (NMDA) receptor
[16, 17]. It also has been shown that beta-alanine can
activate glycine and GABA receptors, though with less
eﬃcacy than their native ligands [18, 19]. As a result of
the promiscuous interaction of beta-alanine with other
receptors precise interpretation of the in vivo studies leading
to insight regarding the role of beta-alanine in nociception is
confounded. Another study was recently published in which
a high-throughput calcium mobilization assay was used for
the identiﬁcation of agonists for MrgD and MrgA. Two
agonists belonging to puridazine and thiazole families were
identiﬁed as hits for MrgD [11]. Ligands for MrgA, another
member of the Mrg family present only in rodents, were also
reported in that study and are of interest from a selectivity
perspective.
When reverse pharmacology approaches are employed
in deorphaning, an open question is whether the ligand
identiﬁed is natural or surrogate [20]. This concern also
applies to beta-alanine. Local concentrations of beta-alanine
previously have been reported to be ∼50μM in rat sciatic
nerve and 60μM in cat brain [21, 22]. EC50 values for
MrgD expressing cell lines have been reported to range
from 8.6μM[ 11], 15 ± 1μM[ 9], and 57.8 + 3.5μM[ 20].
After extensive characterization of ∼100 clones, we were
successful in obtaining cell lines showing EC50 values in
the low micromolar range. Having a ligand (irrespective
of its being cognate or surrogate) and a sensitive cell line
enabled us to develop a robust FLIPR assay with a Z  factor
greater than 0.7 as an aid to identifying both agonists and
antagonists from the same screen. In addition to maximizing
the information that can be obtained about compounds
screened, great cost savings are realized by combining the
two screens into one. We validated the assay by screening
the LOPAC collection. Although the time required to screen
each plate, ∼10 minutes, may be viewed as a shortcoming of
this assay format, we view this as a relatively minor concern
whenbalancedagainsttheamountofdatageneratedandcost
savings from this assay.
In drug discovery, ideally, conﬁrmation of hits identiﬁed
from HTS is done using secondary assays with diﬀerent
end point read outs to eliminate false positive hits. To
further characterize this cell line and explore its utility
for other assays, we investigated G protein coupling by
measuring MrgD responses to beta-alanine after blocking
PLC and Gi. Our results are in agreement with previous
reports that in CHO cells, MrgD signaling occurs primarily
through Gq [9, 11, 14]. However, this observation may
diﬀer across cell types, since in DRG neurons, inhibition
of the M current by beta-alanine activated MrgD occurs
primarily through the Gi pathway [14]. Thus it is pivotal
that interpretation of ﬁndings from a cell line is done
with caution and G protein coupling is studied in native
context.
To ensure that this dual-addition assay format can be
applied to other GPCRs with a known agonist, we also tested
this assay on MrgX1 (data not shown). These experiments
conﬁrmed that this assay format could be extended to
additional GPCRs. In addition to its utility in screening
new targets, this dual-addition assay format also can be
e x t e n d e dt or e c e p t o r ss u c ha sm G l u R sw h e r eb o t ha g o n i s t s
and antagonists have been reported to have therapeutic value
[23].
Antagonists identiﬁed from FLIPR often function as
inverse agonists and can be characterized further by sec-
ondary assays. Having a repertoire of agonists, antagonists
and inverse agonists would be extremely useful in eﬀorts to
validate MrgD. It was not surprising that most of the com-
pounds obtained from the LOPAC screen had EC50 and IC50
values in the micromolar range. Compounds identiﬁed from
this LOPAC screen have very limited utility primarily due
to the lack of selectivity. Chlorpromazine and thioradizine
are both ﬁrst-generation typical antipsychotic drugs and
produce catalepsy in rodents and extrapyramidal side eﬀects
in humans resulting from blockade of D2 receptors [24].Journal of Biomedicine and Biotechnology 7
Chlorpromazineisoftenreferredtoas“dirtydrug”becauseit
actsonmanyreceptorsincludingdopaminergic(D1,D2,D3,
and D4), serotonergic (5-HT1 and 5-HT2), histaminergic
H1, alpha1/alpha2, and muscarinic (M1/M2) receptors [25].
Chlorpromazine is a weak inhibitor of dopamine reup-
take resulting in mild antidepressive and antiparkinsonian
eﬀects. In addition, chlorpromazine inhibits calmodulin-
dependent stimulation of cyclic nucleotide phosphodi-
esterase [26] and nitric oxide synthase [27]. Interestingly
enoughchlorpromazinehasbeenusedforanalgesiaincancer
patients as an adjunct to morphine in advanced cancer
[28, 29].
Thioradizine is a phenothiazine antipsychotic used in
the management of psychoses, including schizophrenia.
However, increased risk of QTc prolongation [30]a n d
sudden death in patients treated with thioridazine has
been reported [31]. The cardiac eﬀects of thioridazine are
related to the concentration-dependent blockade of the
cardiac-delayed inward rectiﬁer potassium channel (Ikr)
[32, 33]. Thioridazine has recently attracted interest as a
potential candidate for development as an antimicrobial
drug. With the emergence of multidrug resistant bacteria,
novel derivatives of thioridazine with reduced aﬃnity for the
Ikr channel and dopamine receptors but higher potency as
antimicrobial have the potential to treat infectious diseases
[34].
HA-966 is an excitatory amino acid antagonist, act-
ing principally at the NMDA receptor subtype through a
selective interaction with the glycine modulatory site of
the receptor complex. Though the mechanism of action
is not well understood, it has been suggested that NMDA
antagonists/opioid combinations have promise as analgesic
agents for the long-term treatment of pain [35].
Thus the antagonistic and agonist activities detected
from screening LOPAC using our MrgD assay may be not
be selective for MrgD. It is also possible that some of
these compounds from the LOPAC collection may be acting
downstream of the receptor, inhibiting Gi, Gq coupling
or any other signaling intermediates. Further studies are
needed to assess the speciﬁc mechanism of action of these
compounds.
The primary objective of this study was to develop an
assay for identiﬁcation of agonists and antagonists from the
same screen. The data presented here demonstrate that the
dual-addition assay format can be successfully employed and
adaptedforHTS.Compoundsidentiﬁedheremayhavesome
utility as positive controls in future screening eﬀorts. It is
often the case in drug discovery that extensive medicinal
chemistry eﬀorts are required to obtain highly potent drug-
like compounds. Thus the compounds identiﬁed here may
provide some insights for further chemistry or structure-
based drug design eﬀorts.
In conclusion, we have developed an HTS assay for
MrgD that will enable the identiﬁcation of both agonists and
antagonists from a single screen and assist in the identiﬁ-
cation of pharmacological tools that will help elucidate the
role of MrgD in pain. Our results demonstrated that the
dual agonist/antagonist assay format is feasible and can be
extended to most GPCRs with a known agonist.
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